Ocular Therapeutix (OCUL) Study Result presentation summary

Forward-looking statements and regulatory status

• Statements about future expectations, plans, and prospects involve substantial risks and uncertainties, including clinical trial outcomes and regulatory approvals.

• Product candidates discussed are investigational and not approved by the FDA or other regulatory agencies.

• Efficacy and safety profiles for AXPAXLI (OTX-TKI) have not been established.

• The company may update forward-looking statements but disclaims any obligation to do so.

Comparative treatment burden reduction analysis

• Post hoc analysis compares AXPAXLI (OTX-TKI) to aflibercept (2 mg) and other therapies over ~1 year.

• With loading doses, AXPAXLI shows a 56% reduction in treatment burden versus aflibercept (3.95 vs 9 injections).

• Without loading doses, AXPAXLI demonstrates a 72% reduction in treatment burden (1.95 vs 7 injections).

• Durability for AXPAXLI measured over 60 weeks, while comparators are measured over 48–52 weeks.

• Results are illustrative and subject to limitations of cross-trial comparisons and differing criteria.

Product and clinical development highlights

• AXPAXLI (OTX-TKI) is being evaluated in SOL-1 and SOL-R Phase 3 trials for wet AMD.

• Plans include advancing AXPAXLI for additional indications such as NPDR.

• Market potential and adoption depend on regulatory approval and clinical outcomes.

• Analysis includes internal data and references to multiple Phase 2 and 3 studies.